# When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

> **NCT00234091** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 300 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir
- **DRUG:** Efavirenz
- **DRUG:** Lamivudine
- **DRUG:** Lopinavir/Ritonavir
- **DRUG:** Nelfinavir
- **DRUG:** Nevirapine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00234091
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2013-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234091, "When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00234091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*